Marietta, Georgia-based life science company MiRus, LLC has announced the hiring of Angela Coldwell as the company’s new Chief Financial Officer. Coldwell comes to MiRus from her most recent role as Chief Financial Officer of oncology life science company Aptitude Health.
Angela Coldwell Named New CFO of MiRus
1 min read Premium comments
Secondary
“We are excited to welcome Angela to MiRus. Her wealth of knowledge and experience will be invaluable in helping MiRus advance our financial systems and achieve important milestones.” said MiRus Founder and CEO Jay S. Yadav, M.D.
Coldwell brings more than 25 years’ experience to MiRus in accounting and finance and a special focus for the past decade in healthcare. Her degree is from Manchester University in the UK, and she is a chartered certified accountant. Her past responsibilities included a variety of investor relations duties, treasury operations, debt and equity financing negotiations and structuring and participating in M&A transactions. Prior to her role at Aptitude Health, Coldwell served as senior finance director at pharmacy and medication management group Curant Health.
MiRus is a global provider of innovative oncology treatments aims to improve orthopedic patient quality of life. MiRus’ mission is to create “innovative medical devices and procedural solutions for the treatment of spine, orthopaedic and structural heart disease.” MiRus takes inspiration from pioneering NASA rocket engine science and has created unique, Rhenium-based medical alloys for use in minimally invasive surgical implants.
In July 2021, MiRus raised $65 million for Rhenium-based alloys in technology for spine, extremity, and structural heart disease devices. The funding round was led by Mammoth Scientific. “This funding will allow us to meet the overwhelming demand from spine surgeons across the country for our highly differentiated products and procedural solutions using the MoRe® superalloy and continue our planned expansion into other important areas including structural heart disease.” Yadav said at the time.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.